News and Trends 9 Dec 2016 Galapagos gets another Milestone Payment from Gilead Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […] December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […] December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Our Startup Battle Winner uses CRISPR in a Whole New Way Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […] December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Lifting the Chemo Fog: Virtual Reality has Medical Applications! Cancer can make life unbearable for some patients, but sometimes the treatment only adds to the pain. Could virtual reality treatments improve their lives? The vast majority of modern cancer therapies are focused on halting the progression and the spread of the disease to save the patient’s life. These treatments are usually aggressive, and approximately […] December 9, 2016 - 3 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn company are Neurimmune, a biotech from Zurich that uses high throughput technology to develop treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, and TVM Capital Life Science. […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 The Munich Biotech Mafia expand to the US with a New TCR Startup TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 UPDATE: No Clear Winner in the CRISPR Patent Battle Today marks an inflection point in the future of medicine: both parties fighting for the ownership of CRISPR have made their oral arguments in front of a jury. Who will win the rights to exploit a technology that could be used to cure any genetic disease? CRISPR has been hailed as the ‘scientific discovery of the […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Video: How is European Biotech changing the World? We had the amazing opportunity to hear an overview of biotech in Europe at Labiotech Refresh from Philippe Pouletty, co-founder and managing director of Truffle Capital. Philippe has an incredibly extensive experience in biotech as a founder of multiple companies and VCs. He witnessed how biotech got big over the years with the first innovations coming […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […] December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Ask the Biotech Recruiter: Here are 7 Signs it’s Time to Talk to the Headhunters Finding a new executive is never easy. Is it time to ask for help? The biotech headhunters at Pact & Partners can lend a hand! How long have you been looking to fill a top-level position at your company? Is it taking more time than expected, and are you stuck scratching your head? Are you […] December 7, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 UPDATE: More Good News on a Cannabis Derivative for Epilepsy Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published on 27/09/2016 GW Pharmaceuticals just released the results of its third successful Phase III clinical trial for Epidiolex (cannabidiol), a drug that can reduce the frequency of […] December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2016 Sanofi Jumps into the Biosimilars Market aiming for Asia Sanofi is joining the biosimilars trend to challenge Roche’s best-selling biological with a partnership that aims to take over the Chinese cancer market. Sanofi is going after the €6.8B ($7.3B) that Roche’s Rituxan/MabThera (rituximab), the second top-selling biological, made last year in revenues. The French pharma has signed a deal worth up to €219M ($236M) […] December 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email